Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Calendar
Screener
News
About

Home

/

GNPX

G

Genprex, Inc. (GNPX)

NCM – Real Time Price. Currency in USD

4.33

-0.14 (-3.13%)

Market open: Aug 12, 2026, 10:21 AM EDT

4.47

+0.00 (0.05%)

Previous after-hours: Aug 11, 2026, 7:51 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology Validation Studies Aim to Optimize Clinical Trial Patient Selection Criteria AUSTIN, Texas, Aug. 3, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.

Videos

No Data

There is no data to display

Press releases

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology Validation Studies Aim to Optimize Clinical Trial Patient Selection Criteria AUSTIN, Texas, Aug. 3, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.